Mesoblast fuses Phase II
Tuesday, 28 April, 2009
Melbourne’s Mesoblast has received approval to being a Phase II trial of its allogeneic stem cell product NeoFuse in cervical spine fusion.
The trial, to be held at Melbourne’s Epworth Hospital, will compare NeoFuse with autograft. Twenty-four patients with irreversible, end-stage degenerative disc disease will take part in the randomised, controlled trial.
Mesoblast is also working on lumbar spinal fusion and on repair or regeneration of discs in patients with earlier stage disease.
TGA acts on melatonin imports with infringement notices totalling $99K
Laboratory testing of several imported unregistered melatonin products has confirmed them to be...
Scientists search for cystitis pain 'off switch'
By targeting certain pain receptors in the bladder, Australian scientists believe that the...
Australia's first cases of H5 avian influenza confirmed
Positive results for H5 avian influenza (bird flu) have been confirmed in two seabirds found in...
